Aprea Therapeutics

Aprea Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of cancer therapies that reactivate mutant p53 tumor suppressor protein. Its lead product candidate, APR-246, is a small molecule p53 reactivator in late-stage clinical development for hematological malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).